ES2356308T3 - Uso de derivados peptídicos para inducir la diferenciación celular. - Google Patents
Uso de derivados peptídicos para inducir la diferenciación celular. Download PDFInfo
- Publication number
- ES2356308T3 ES2356308T3 ES03743087T ES03743087T ES2356308T3 ES 2356308 T3 ES2356308 T3 ES 2356308T3 ES 03743087 T ES03743087 T ES 03743087T ES 03743087 T ES03743087 T ES 03743087T ES 2356308 T3 ES2356308 T3 ES 2356308T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- dicarbamine
- baselineskip
- cells
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 230000024245 cell differentiation Effects 0.000 title abstract description 16
- 201000001441 melanoma Diseases 0.000 claims abstract description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 125000003368 amide group Chemical group 0.000 claims abstract description 3
- 125000003277 amino group Chemical group 0.000 claims abstract description 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 3
- 238000002512 chemotherapy Methods 0.000 claims description 80
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 238000002560 therapeutic procedure Methods 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 23
- 208000004235 neutropenia Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 12
- 229940079322 interferon Drugs 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- 229930195733 hydrocarbon Natural products 0.000 claims description 8
- 206010043554 thrombocytopenia Diseases 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 99
- 230000000694 effects Effects 0.000 abstract description 60
- 210000004881 tumor cell Anatomy 0.000 abstract description 23
- 239000000824 cytostatic agent Substances 0.000 abstract description 12
- 230000001085 cytostatic effect Effects 0.000 abstract description 10
- 210000002780 melanosome Anatomy 0.000 abstract description 8
- 239000000411 inducer Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 4
- 125000004442 acylamino group Chemical group 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- KZIMLUFVKJLCCH-UHFFFAOYSA-N 5-[2-(1h-imidazol-5-yl)ethylamino]-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)NCCC1=CNC=N1 KZIMLUFVKJLCCH-UHFFFAOYSA-N 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- -1 cyclic imide Chemical class 0.000 abstract 1
- 238000003304 gavage Methods 0.000 abstract 1
- 238000011580 nude mouse model Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 230000004069 differentiation Effects 0.000 description 39
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 29
- 229960004397 cyclophosphamide Drugs 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 28
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 27
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 24
- 229960004562 carboplatin Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 210000001185 bone marrow Anatomy 0.000 description 19
- 230000012010 growth Effects 0.000 description 19
- 210000000805 cytoplasm Anatomy 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 17
- 108010047761 Interferon-alpha Proteins 0.000 description 15
- 102000006992 Interferon-alpha Human genes 0.000 description 15
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 231100000226 haematotoxicity Toxicity 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 238000001493 electron microscopy Methods 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 108010078049 Interferon alpha-2 Proteins 0.000 description 10
- 206010028851 Necrosis Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- 238000009534 blood test Methods 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 210000003714 granulocyte Anatomy 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010049466 Erythroblastosis Diseases 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000002489 hematologic effect Effects 0.000 description 7
- 201000002364 leukopenia Diseases 0.000 description 7
- 230000011278 mitosis Effects 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 210000003887 myelocyte Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108010034791 Heterochromatin Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000002012 hematotoxic effect Effects 0.000 description 4
- 210000004458 heterochromatin Anatomy 0.000 description 4
- 210000003924 normoblast Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000004765 promyelocyte Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 206010061188 Haematotoxicity Diseases 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000003039 myelosuppressive effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000000399 optical microscopy Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BADMGRJDJPQBLS-UNTFVMJOSA-N 1-methyl-1-nitroso-3-[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]urea Chemical compound O=NN(C)C(=O)N[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O BADMGRJDJPQBLS-UNTFVMJOSA-N 0.000 description 2
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 231100000605 Toxicity Class Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 239000012568 clinical material Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002895 hyperchromatic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WAAZXLNQUDXDRP-VIFPVBQESA-N (3S)-3-acetamido-4-[2-(1H-imidazol-5-yl)ethylamino]-4-oxobutanoic acid Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)NCCC1=CNC=N1 WAAZXLNQUDXDRP-VIFPVBQESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 231100000042 hematotoxic Toxicity 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000010644 positive regulation of cell differentiation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 125000005289 uranyl group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2002105392/14A RU2217196C2 (ru) | 2002-02-28 | 2002-02-28 | Способ индукции дифференцировки клеток |
| RU2002105392 | 2002-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2356308T3 true ES2356308T3 (es) | 2011-04-06 |
Family
ID=27764932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03743087T Expired - Lifetime ES2356308T3 (es) | 2002-02-28 | 2003-02-28 | Uso de derivados peptídicos para inducir la diferenciación celular. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7759313B2 (enExample) |
| EP (1) | EP1491206B9 (enExample) |
| JP (1) | JP4711626B2 (enExample) |
| CN (1) | CN1649612B (enExample) |
| AT (1) | ATE488234T1 (enExample) |
| AU (1) | AU2003235538A1 (enExample) |
| CY (1) | CY1111265T1 (enExample) |
| DE (1) | DE60334978D1 (enExample) |
| DK (1) | DK1491206T3 (enExample) |
| EA (1) | EA007474B1 (enExample) |
| ES (1) | ES2356308T3 (enExample) |
| HK (1) | HK1079990B (enExample) |
| IL (3) | IL163763A0 (enExample) |
| PT (1) | PT1491206E (enExample) |
| RU (1) | RU2217196C2 (enExample) |
| SI (1) | SI1491206T1 (enExample) |
| UA (1) | UA85039C2 (enExample) |
| WO (1) | WO2003072124A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC200060A1 (fr) | 2002-10-04 | 2003-05-28 | M Exsymol Sa | Produit de couplage entre la tryptamine et un alpha-aminoacide son procédé de préparation et son application dans le domaine de la neuro-cosmétique |
| RU2335495C2 (ru) * | 2005-06-15 | 2008-10-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
| RU2373934C1 (ru) * | 2008-03-19 | 2009-11-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств |
| RU2359030C1 (ru) * | 2008-03-19 | 2009-06-20 | Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" | Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты) |
| JP5370957B2 (ja) | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
| KR101414942B1 (ko) * | 2010-10-22 | 2014-07-04 | 코럼 아이엔씨 | 멜라닌 생성을 억제하는 글리신 유도체 및 그 미백 조성물 |
| CN104257515B (zh) * | 2010-10-22 | 2017-05-03 | 新钰生技股份有限公司 | 具有抑制黑色素生成的甘胺酸衍生物及使用其的美白组成物 |
| UA115431C2 (uk) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Застосування глутарилгістаміну для лікування захворювань дихальних шляхів |
| CN103382179A (zh) * | 2013-06-05 | 2013-11-06 | 四川百利药业有限责任公司 | 英加韦林的多晶型物及其制备方法 |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| SG11202102821QA (en) * | 2018-09-25 | 2021-04-29 | Myelo Therapeutics Gmbh | Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation |
| RU2726119C1 (ru) * | 2019-11-22 | 2020-07-09 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новые производные полиолов, их применение, фармацевтическая композиция на их основе |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6016926A (ja) * | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
| JPS6016934A (ja) * | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
| US4816442A (en) * | 1986-11-07 | 1989-03-28 | Collagen Corporation | Method of inhibiting tumor growth sensitive to CIF-βtreatment |
| JPS6442430A (en) * | 1987-08-11 | 1989-02-14 | Nippon Univ | Side effect remover for chemotherapeutic agent |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| JPH0585942A (ja) | 1991-02-26 | 1993-04-06 | Denki Kagaku Kogyo Kk | インターフエロン−ヒアルロン酸及び／又はその塩の結合体 |
| CA2108584C (en) * | 1992-10-27 | 1998-11-24 | James B. Doherty | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| GB9308695D0 (en) * | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| AU696167B2 (en) | 1993-10-29 | 1998-09-03 | Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| JP3517274B2 (ja) * | 1994-05-20 | 2004-04-12 | 株式会社ナリス化粧品 | 皮膚組成物 |
| RU2120298C1 (ru) * | 1995-11-28 | 1998-10-20 | Товарищество с ограниченной ответственностью "Верта" | Иммуностимулятор и препарат на его основе |
| FR2762315B1 (fr) * | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
| RU2141483C1 (ru) * | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| DE69840451D1 (de) * | 1997-11-07 | 2009-02-26 | Mayo Foundation | Interferon-immuntherapie mit niedriger dosis |
| US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| AU768269B2 (en) * | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
-
2002
- 2002-02-28 RU RU2002105392/14A patent/RU2217196C2/ru not_active IP Right Cessation
-
2003
- 2003-02-28 EP EP03743087A patent/EP1491206B9/en not_active Expired - Lifetime
- 2003-02-28 UA UA20040907835A patent/UA85039C2/uk unknown
- 2003-02-28 CN CN038094959A patent/CN1649612B/zh not_active Expired - Lifetime
- 2003-02-28 DK DK03743087.3T patent/DK1491206T3/da active
- 2003-02-28 AT AT03743087T patent/ATE488234T1/de active
- 2003-02-28 EA EA200401105A patent/EA007474B1/ru unknown
- 2003-02-28 HK HK06100072.5A patent/HK1079990B/zh not_active IP Right Cessation
- 2003-02-28 AU AU2003235538A patent/AU2003235538A1/en not_active Abandoned
- 2003-02-28 DE DE60334978T patent/DE60334978D1/de not_active Expired - Lifetime
- 2003-02-28 IL IL16376303A patent/IL163763A0/xx unknown
- 2003-02-28 ES ES03743087T patent/ES2356308T3/es not_active Expired - Lifetime
- 2003-02-28 PT PT03743087T patent/PT1491206E/pt unknown
- 2003-02-28 US US10/505,976 patent/US7759313B2/en not_active Expired - Lifetime
- 2003-02-28 WO PCT/RU2003/000072 patent/WO2003072124A1/ru not_active Ceased
- 2003-02-28 JP JP2003570868A patent/JP4711626B2/ja not_active Expired - Lifetime
- 2003-02-28 SI SI200331938T patent/SI1491206T1/sl unknown
-
2004
- 2004-08-26 IL IL163763A patent/IL163763A/en active IP Right Grant
-
2010
- 2010-11-30 IL IL209653A patent/IL209653A0/en unknown
-
2011
- 2011-02-09 CY CY20111100154T patent/CY1111265T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1491206B9 (en) | 2011-03-09 |
| WO2003072124A1 (en) | 2003-09-04 |
| CN1649612A (zh) | 2005-08-03 |
| HK1079990B (zh) | 2011-12-09 |
| HK1079990A1 (en) | 2006-04-21 |
| US20050180953A1 (en) | 2005-08-18 |
| EA200401105A1 (ru) | 2004-12-30 |
| JP2005532269A (ja) | 2005-10-27 |
| AU2003235538A1 (en) | 2003-09-09 |
| PT1491206E (pt) | 2011-02-11 |
| EP1491206A4 (en) | 2006-01-11 |
| US7759313B2 (en) | 2010-07-20 |
| ATE488234T1 (de) | 2010-12-15 |
| UA85039C2 (uk) | 2008-12-25 |
| EP1491206A1 (en) | 2004-12-29 |
| JP4711626B2 (ja) | 2011-06-29 |
| IL209653A0 (en) | 2011-02-28 |
| RU2217196C2 (ru) | 2003-11-27 |
| DE60334978D1 (de) | 2010-12-30 |
| DK1491206T3 (da) | 2011-03-14 |
| SI1491206T1 (sl) | 2011-03-31 |
| EA007474B1 (ru) | 2006-10-27 |
| EP1491206B1 (en) | 2010-11-17 |
| IL163763A (en) | 2011-12-29 |
| IL163763A0 (en) | 2005-12-18 |
| CY1111265T1 (el) | 2015-08-05 |
| CN1649612B (zh) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2356308T3 (es) | Uso de derivados peptídicos para inducir la diferenciación celular. | |
| ES2235499T3 (es) | Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena. | |
| Tampellini et al. | Docetaxel chronopharmacology in mice | |
| ES2702128T3 (es) | Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación | |
| RU2481853C2 (ru) | Улучшенные способы лечения опухолей | |
| JP4057648B2 (ja) | 造血前駆細胞の増殖を促進するチオール類 | |
| JPH10505834A (ja) | 化学療法または放射線療法の間の造血細胞の保護 | |
| US5955432A (en) | Metabolic effects of certain glutathione analogs | |
| RU2730998C2 (ru) | Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении | |
| Chen et al. | Carrageenan-ferrocene-eicosapentaenoic acid composite hydrogel induce ferroptosis and apoptosis for anti-tumor recurrence and metastasis | |
| CN116726021A (zh) | 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途 | |
| US20090232906A1 (en) | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions | |
| WO2020217472A1 (ja) | 治療抵抗性がんの予防又は治療用の医薬組成物 | |
| Li et al. | Inhibition of growth of human nasopharyngeal cancer xenografts in SCID mice by arsenic trioxide | |
| CA2717181A1 (en) | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions | |
| KR102694803B1 (ko) | A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용 | |
| RU2317074C1 (ru) | Ингибитор дифференцировки кроветворных клеток-предшественников | |
| CN109985030B (zh) | 醌式查尔酮化合物在制备抗肿瘤药物中的应用 | |
| Teicher et al. | Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma | |
| CN115137831B (zh) | 虾青素在制备抗血管生成药物增效剂中的应用以及一种药物组合物 | |
| US20110124741A1 (en) | Radiosensitizer compositions comprising schisandra chinensis(turcz.)baill and methods for use | |
| JP3816522B2 (ja) | 造血機能に関して刺激活性を示すｍｄｐ誘導体および複合体ならびにそれらを含む組成物 | |
| CN104688748A (zh) | 一种含有熊果酸和环磷酰胺的药物组合物 | |
| RU2782931C2 (ru) | Производные индол-3-карбоновой кислоты, обладающие противоопухолевой активностью | |
| US20110256236A1 (en) | Enhancement of the Anti-Leukemic Effect of Thalidomide |